Neurosense, FDA to Meet Nov. 6 to Discuss Design of Amyotrophic Lateral Sclerosis Treatment Trial; Shares Rise

MT Newswires Live10-28

NeuroSense Therapeutics (NRSN) said Monday it is scheduled for a type C meeting with the US Food and Drug Administration Nov. 6 to discuss the design of a phase 3 clinical trial for its lead drug candidate PrimeC for the potential treatment of amyotrophic lateral sclerosis.

The company plans to provide an update on meeting results after receiving the meeting minutes, which are expected roughly one month after the event, it said.

NeuroSense also said it plans to submit its regulatory dossier to Health Canada in Q2, with a regulatory decision expected by Q1 2026.

ALS is an incurable neurodegenerative disease that causes complete paralysis and death within two to five years from diagnosis, the company said. NeuroSense said its PrimeC has shown 'promising' results in clinical trials, including a statistically significant reduction in disease progression clinical and biological markers.

NeuroSense shares were up 3.2% in recent Monday trading.

Price: 1.31, Change: +0.04, Percent Change: +3.15

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478487959?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-28 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478487959","market":"sg","top_or_hot":-1,"title":"Neurosense, FDA to Meet Nov. 6 to Discuss Design of Amyotrophic Lateral Sclerosis Treatment Trial; Shares Rise","media":"MT Newswires Live","content":"<html><body><p> NeuroSense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (NRSN) said Monday it is scheduled for a type C meeting with the US Food and Drug Administration Nov. 6 to discuss the design of a phase 3 clinical trial for its lead drug candidate PrimeC for the potential treatment of amyotrophic lateral sclerosis.</p><p>The company plans to provide an update on meeting results after receiving the meeting minutes, which are expected roughly one month after the event, it said.</p><p>NeuroSense also said it plans to submit its regulatory dossier to Health Canada in Q2, with a regulatory decision expected by Q1 2026.</p><p>ALS is an incurable neurodegenerative disease that causes complete paralysis and death within two to five years from diagnosis, the company said. NeuroSense said its PrimeC has shown 'promising' results in clinical trials, including a statistically significant reduction in disease progression clinical and biological markers.</p><p>NeuroSense shares were up 3.2% in recent Monday trading.</p><p>Price: 1.31, Change: +0.04, Percent Change: +3.15</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurosense, FDA to Meet Nov. 6 to Discuss Design of Amyotrophic Lateral Sclerosis Treatment Trial; Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurosense, FDA to Meet Nov. 6 to Discuss Design of Amyotrophic Lateral Sclerosis Treatment Trial; Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-28 22:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NeuroSense Therapeutics (NRSN) said Monday it is scheduled for a type C meeting with the US Food and Drug Administration Nov. 6 to discuss the design of a phase 3 clinical trial for its lead drug ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2478487959","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478487959","pubTimestamp":1730126877,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"NeuroSense Therapeutics  said Monday it is scheduled for a type C meeting with the US Food and Drug Administration Nov. 6 to discuss the design of a phase 3 clinical trial for its lead drug candidate PrimeC for the potential treatment of amyotrophic lateral sclerosis.The company plans to provide an update on meeting results after receiving the meeting minutes, which are expected roughly one month after the event, it said.NeuroSense also said it plans to submit its regulatory dossier to Health Canada in Q2, with a regulatory decision expected by Q1 2026.ALS is an incurable neurodegenerative disease that causes complete paralysis and death within two to five years from diagnosis, the company said. NeuroSense said its PrimeC has shown 'promising' results in clinical trials, including a statistically significant reduction in disease progression clinical and biological markers.NeuroSense shares were up 3.2% in recent Monday trading.Price: 1.31, Change: +0.04, Percent Change: +3.15","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NRSN":"Neurosense Therapeutics Ltd"},"translate_title":"Neurosense与FDA将于11月6日会面，讨论肌萎缩侧索硬化症治疗试验的设计；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRSN":0.9},"content_text":"NeuroSense Therapeutics (NRSN) said Monday it is scheduled for a type C meeting with the US Food and Drug Administration Nov. 6 to discuss the design of a phase 3 clinical trial for its lead drug candidate PrimeC for the potential treatment of amyotrophic lateral sclerosis.The company plans to provide an update on meeting results after receiving the meeting minutes, which are expected roughly one month after the event, it said.NeuroSense also said it plans to submit its regulatory dossier to Health Canada in Q2, with a regulatory decision expected by Q1 2026.ALS is an incurable neurodegenerative disease that causes complete paralysis and death within two to five years from diagnosis, the company said. NeuroSense said its PrimeC has shown 'promising' results in clinical trials, including a statistically significant reduction in disease progression clinical and biological markers.NeuroSense shares were up 3.2% in recent Monday trading.Price: 1.31, Change: +0.04, Percent Change: +3.15","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478487959"}